{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:18:27Z","timestamp":1775470707838,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":131,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Andrology"],"published-print":{"date-parts":[[2001,8,12]]},"abstract":"<jats:p>This randomized, prospective study compared three treatments, nandrolone decanoate (ND), megestrol acetate (MA) or dietary counselling, for managing human immunodeficiency syndrome (HIV) associated weight loss. It was centred on a Tertiary referral hospital, Sydney, Australia. Fifteen patients were randomized to receive ND (100\u2003mg\/fortnight), or MA (400\u2003mg\/day) or dietary counselling for 12\u2003weeks. Those patients randomized to dietary counselling were further randomized to receive nandrolone or megestrol after completing the dietary counselling arm. Weight, fat free mass (FFM), percentage body fat mass (FM), dietary intake and appetite were assessed before commencing and at the completion of each treatment arm. Weight increased significantly in all treatment arms (dietary counselling 1.13\u2003kg\u2003\u00b1\u20030.36, nandrolone 4.01\u2003kg\u2003\u00b1\u20031.68, megestrol 10.20\u2003kg\u2003\u00b1\u20034.51, <jats:italic>p\u2003<\/jats:italic>&lt;\u20030.05 paired <jats:italic>t<\/jats:italic>\u2010test). FFM increased significantly in patients receiving ND (3.54\u2003\u00b1\u20031.98\u2003kg, <jats:italic>p<\/jats:italic>=0.001) and those receiving MA (2.76\u2003\u00b1\u20030.55\u2003kg, <jats:italic>p<\/jats:italic>=0.002), whereas the change in those receiving dietary counselling alone was not significant. Percentage body fat mass increased significantly only in those receiving MA (7.77\u2003\u00b1\u20034.85%, <jats:italic>p<\/jats:italic>=0.049). The change in weight and percentage body fat mass was significantly greater in those receiving MA than the other two treatment arms. The increase in FFM was significantly greater in both the nandrolone and megestrol arms than the dietary counselling arm. It was concluded that ND and MA both resulted in an increase in FFM greater than dietary counselling alone. Megestrol produced a significantly greater increase in weight, percentage fat mass, intake and appetite than did the other two treatment arms, suggesting it may be the preferred agent, particularly in a palliative care setting in which weight, appetite and intake increase are desirable without regard to the composition of the body. The long\u2010term use of these agents in people with HIV should be reviewed in the context of improved survival on highly active antiretroviral therapy regimens.<\/jats:p>","DOI":"10.1046\/j.1365-2605.2001.00291.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T01:05:58Z","timestamp":1047431158000},"page":"232-240","source":"Crossref","is-referenced-by-count":40,"title":["A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss"],"prefix":"10.1111","volume":"24","author":[{"given":"Marijka Jane","family":"Batterham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Garsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"II","article-title":"Calculation energy requirements for people with HIV\/AIDS","volume":"15","author":"Batterham M.","year":"1999","journal-title":"Nutrition"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00020"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09652149932316"},{"key":"e_1_2_6_5_2","first-page":"36","article-title":"Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer","volume":"12","author":"Bonomi P.","year":"1985","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(96)00158-7"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1997.03540480062040","article-title":"Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society \u2013 USA panel","volume":"277","author":"Carpenter C. C.","year":"1997","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007676625117"},{"key":"e_1_2_6_10_2","first-page":"1288","article-title":"Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS","volume":"84","author":"Chlebowski R. T.","year":"1989","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(95)00115-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906033402207"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/42.6.1170"},{"key":"e_1_2_6_14_2","first-page":"107","article-title":"Changes in body habitus and serum lipid abnormalities in HIV\u2010positive women of highly active antiretroviral therapy (HAART)","volume":"21","author":"Dong K. L.","year":"1999","journal-title":"JAIDS"},{"key":"e_1_2_6_15_2","first-page":"222","article-title":"Effects of megestrol acetate therapy upon body composition and serum testosterone in AIDS","volume":"10","author":"Engelson E. S.","year":"1994","journal-title":"X International Conference on AIDS"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0899-9007(99)00053-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/archinte.1991.00400100013003","article-title":"Atherogenic effects of anabolic steroids on serum lipid levels. A literature review","volume":"151","author":"Glazer G.","year":"1991","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90246-1"},{"key":"e_1_2_6_19_2","first-page":"558","article-title":"Nandrolone decanoate; use in HIV\u2010associated lipodystrophy syndrome: a pilot study","volume":"10","author":"Gold J.","year":"1999","journal-title":"International Journal of STD & AIDS"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199606001-00008"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-1-199807010-00005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02388-6"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90238-9"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-53"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.14.1275"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-6-199603150-00017"},{"key":"e_1_2_6_27_2","unstructured":"Kopera H.(1993a)Anabolic steroids in deficiency states. In:Anabolic\u2013Androgenic Steroids Towards 2000(ed. H. Kopera) pp. 225\u2013226. Blackwell\u2010MZV Vienna."},{"key":"e_1_2_6_28_2","unstructured":"Kopera H.(1993b)Side effects and contraindications of anabolic steroids. In:Anabolic\u2013Androgenic Steroids Towards the Year 2000(ed. H. Kopera). pp. 262\u2013264. Blackwell\u2010MZV Vienna."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/50.3.444"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-11-199506010-00006"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)11443-x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-6-199603150-00016"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/64.3.397S"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.1999.13.287"},{"key":"e_1_2_6_35_2","first-page":"880","article-title":"Megestrol for AIDS\u2010related anorexia[letter]","volume":"122","author":"Maurer M.","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0899-9007(99)00210-5"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)11518-5"},{"key":"e_1_2_6_38_2","first-page":"43","article-title":"Megestrol acetate vs tamoxifen in advanced breast cancer in postmenopausal patients","volume":"12","author":"Morgan L.","year":"1985","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_39_2","unstructured":"Mulligan K. Tai V. W. Chernoff D. N. Schambelan M.(1997)Viral load and resting energy expenditure in men with HIV infection. In:Fourth Conference on Retroviruses and Opportunistic Infection Abstract 192 Washington DC 22\u201326 January 1997."},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidaemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan K.","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"key":"e_1_2_6_41_2","first-page":"S4","article-title":"Nutrition in human immunodeficiency virus (HIV) disease","volume":"49","author":"Oliver C.","year":"1992","journal-title":"Australian Journal of Nutrition & Dietetics"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00002"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-10-878_1"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00777.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.4.1268"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-11-199612010-00002"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-6-199603150-00018"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199902010-00005"},{"key":"e_1_2_6_49_2","unstructured":"US Centers for Disease Control(1992)1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.Morbidity & Mortality Weekly Report (MMWR) 41 (RR\u201017) 1\u201319."},{"key":"e_1_2_6_50_2","first-page":"156","article-title":"When and where to start: guidelines for the initiation of antiretroviral therapy","volume":"10","author":"Volberding P.","year":"2000","journal-title":"AIDS Reader"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00001"}],"container-title":["International Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2605.2001.00291.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2605.2001.00291.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T20:50:48Z","timestamp":1697662248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2605.2001.00291.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,8,12]]}},"alternative-id":["10.1046\/j.1365-2605.2001.00291.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2605.2001.00291.x","archive":["Portico"],"relation":{},"ISSN":["0105-6263","1365-2605"],"issn-type":[{"value":"0105-6263","type":"print"},{"value":"1365-2605","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,12]]}}}